TCR2 THERAPEUTICS INC (TCRR) Stock Fundamental Analysis

USA • Nasdaq • NASDAQ:TCRR • US87808K1060

1.48 USD
-0.09 (-5.73%)
At close: May 31, 2023
1.53 USD
+0.05 (+3.38%)
After Hours: 5/31/2023, 8:00:02 PM
Fundamental Rating

2

TCRR gets a fundamental rating of 2 out of 10. The analysis compared the fundamentals against 524 industry peers in the Biotechnology industry. TCRR scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. TCRR is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year TCRR has reported negative net income.
  • In the past year TCRR has reported a negative cash flow from operations.
TCRR Yearly Net Income VS EBIT VS OCF VS FCFTCRR Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 -50M -100M -150M

1.2 Ratios

  • TCRR has negative profitability rations, so we won't be analyzing them here.
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
TCRR Yearly ROA, ROE, ROICTCRR Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 -20 -40 -60 -80 -100

1.3 Margins

  • The Profit Margin and Operating Margin and Gross Margin are not available for TCRR so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
TCRR Yearly Profit, Operating, Gross MarginsTCRR Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022

More info and screens

5

2. Health

2.1 Basic Checks

  • The number of shares outstanding for TCRR has been increased compared to 1 year ago.
  • TCRR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
TCRR Yearly Shares OutstandingTCRR Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 10M 20M 30M
TCRR Yearly Total Debt VS Total AssetsTCRR Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 100M 200M 300M

2.2 Solvency

  • Based on the Altman-Z score of -6.44, we must say that TCRR is in the distress zone and has some risk of bankruptcy.
  • TCRR has a worse Altman-Z score (-6.44) than 70.08% of its industry peers.
  • TCRR has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -6.44
ROIC/WACCN/A
WACCN/A
TCRR Yearly LT Debt VS Equity VS FCFTCRR Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 0 100M -100M 200M

2.3 Liquidity

  • TCRR has a Current Ratio of 2.96. This indicates that TCRR is financially healthy and has no problem in meeting its short term obligations.
  • The Current ratio of TCRR (2.96) is worse than 69.28% of its industry peers.
  • TCRR has a Quick Ratio of 2.96. This indicates that TCRR is financially healthy and has no problem in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 2.96, TCRR is doing worse than 68.16% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 2.96
Quick Ratio 2.96
TCRR Yearly Current Assets VS Current LiabilitesTCRR Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 50M 100M 150M 200M 250M

More info and screens

1

3. Growth

3.1 Past

  • TCRR shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -49.47%.
EPS 1Y (TTM)-49.47%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-35.53%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

  • TCRR is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 16.12% yearly.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y42.95%
EPS Next 2Y25.45%
EPS Next 3Y17.13%
EPS Next 5Y16.12%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
TCRR Yearly Revenue VS EstimatesTCRR Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 100M 200M 300M
TCRR Yearly EPS VS EstimatesTCRR Yearly EPS VS EstimatesYearly EPS VS Estimates 2018 2019 2020 2021 2022 2023 2024 2025 2026 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

  • TCRR reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
  • Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for TCRR. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
TCRR Price Earnings VS Forward Price EarningsTCRR Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
TCRR Per share dataTCRR EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 -4

4.3 Compensation for Growth

  • TCRR's earnings are expected to grow with 17.13% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y25.45%
EPS Next 3Y17.13%

More info and screens

0

5. Dividend

5.1 Amount

  • No dividends for TCRR!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

TCR2 THERAPEUTICS INC / TCRR FAQ

What is the fundamental rating for TCRR stock?

ChartMill assigns a fundamental rating of 2 / 10 to TCRR.


What is the valuation status of TCR2 THERAPEUTICS INC (TCRR) stock?

ChartMill assigns a valuation rating of 3 / 10 to TCR2 THERAPEUTICS INC (TCRR). This can be considered as Overvalued.


What is the profitability of TCRR stock?

TCR2 THERAPEUTICS INC (TCRR) has a profitability rating of 1 / 10.